Evidence map›Paper›PMID 39188280›Full record

ReviewSmart medicine2023

Stimuli-responsive silk fibroin for on-demand drug delivery.

Xiang Lin, Lijun Cai, Xinyue Cao, Yuanjin Zhao

Abstract readReview
In one paragraph

Review in Smart medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiang LinDepartment of Rheumatology and Immunology Nanjing Drum Tower Hospital School of Biological Science and Medical Engineering, Southeast University Nanjing China.ORCID https://orcid.org/0000-0002-8789-1197
Lijun CaiDepartment of Rheumatology and Immunology Nanjing Drum Tower Hospital School of Biological Science and Medical Engineering, Southeast University Nanjing China.
Xinyue CaoDepartment of Rheumatology and Immunology Nanjing Drum Tower Hospital School of Biological Science and Medical Engineering, Southeast University Nanjing China.
Yuanjin ZhaoDepartment of Rheumatology and Immunology Nanjing Drum Tower Hospital School of Biological Science and Medical Engineering, Southeast University Nanjing China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stimuli-responsive "smart" hydrogel biomaterials have attracted great attention in the biomedical field, especially in designing novel on-demand drug delivery systems. As a handful natural biomaterial approved by US Food and Drug Administration, silk fibroin (SF) has unique high temperature resistance as well as tunable structural composition. These properties make it one of the most ideal candidates for on-demand drug delivery. Meanwhile, recent advances in polymer modification and nanomaterials have fostered the development of various stimuli-responsive delivery systems. Here, we first review the recent advance in designing responsive SF-based delivery systems in different stimulus sources. These systems are able to release mediators in a desired manner in response to specific stimuli in active or passive manners. We then describe applications of these specially designed responsive delivery systems in wound healing, tumor therapy, as well as immunomodulation. We also discuss the future challenges and prospects of stimuli-responsive SF-based delivery systems.

Indexed as

biomedicalhydrogelon‐demand drug deliverysilk fibroinstimuli‐responsive

Identifiers

PMID39188280
PMCPMC11235688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.